BRPI0906104A2 - "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto" - Google Patents
"derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"Info
- Publication number
- BRPI0906104A2 BRPI0906104A2 BRPI0906104-5A BRPI0906104A BRPI0906104A2 BR PI0906104 A2 BRPI0906104 A2 BR PI0906104A2 BR PI0906104 A BRPI0906104 A BR PI0906104A BR PI0906104 A2 BRPI0906104 A2 BR PI0906104A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- acid derivative
- peptide nucleic
- pharmaceutical composition
- effective amount
- Prior art date
Links
- 108091093037 Peptide nucleic acid Proteins 0.000 title 4
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20080023658 | 2008-03-14 | ||
| KR10-2008-23658 | 2008-03-14 | ||
| KR10-2008-111459 | 2008-11-11 | ||
| KR20080111459 | 2008-11-11 | ||
| PCT/KR2009/001256 WO2009113828A2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0906104A2 true BRPI0906104A2 (pt) | 2015-06-30 |
| BRPI0906104B1 BRPI0906104B1 (pt) | 2021-03-30 |
| BRPI0906104B8 BRPI0906104B8 (pt) | 2021-05-25 |
Family
ID=41065678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906104A BRPI0906104B8 (pt) | 2008-03-14 | 2009-03-13 | derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8680253B2 (pt) |
| EP (1) | EP2268607B9 (pt) |
| JP (1) | JP5620282B2 (pt) |
| KR (2) | KR20090098710A (pt) |
| CN (1) | CN102015628B (pt) |
| AU (1) | AU2009224149B2 (pt) |
| BR (1) | BRPI0906104B8 (pt) |
| CA (1) | CA2715844C (pt) |
| DK (1) | DK2268607T5 (pt) |
| ES (1) | ES2533769T3 (pt) |
| IL (4) | IL207617A (pt) |
| MX (1) | MX2010009687A (pt) |
| NZ (1) | NZ587448A (pt) |
| PL (1) | PL2268607T3 (pt) |
| PT (1) | PT2268607E (pt) |
| RU (1) | RU2564032C2 (pt) |
| WO (1) | WO2009113828A2 (pt) |
| ZA (1) | ZA201005960B (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU198825B (en) | 1987-03-09 | 1989-12-28 | Chinoin Gyogyszer Es Vegyeszet | Synergic fungicides |
| US9234059B2 (en) | 2008-07-16 | 2016-01-12 | Outlast Technologies, LLC | Articles containing functional polymeric phase change materials and methods of manufacturing the same |
| US8221910B2 (en) | 2008-07-16 | 2012-07-17 | Outlast Technologies, LLC | Thermal regulating building materials and other construction components containing polymeric phase change materials |
| TW201726630A (zh) * | 2009-10-16 | 2017-08-01 | 梅林塔療法公司 | 抗微生物性化合物及其製造與使用方法 |
| KR101972992B1 (ko) * | 2009-10-16 | 2019-04-29 | 멜린타 서브시디어리 코프. | 항미생물성 화합물 및 이의 제조 방법 및 사용 방법 |
| US9216979B2 (en) | 2009-10-16 | 2015-12-22 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| WO2011047320A2 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
| KR20140065378A (ko) | 2011-04-15 | 2014-05-29 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 그의 제조 방법과 사용 방법 |
| CN103031337A (zh) * | 2012-09-28 | 2013-04-10 | 北京吉利奥生物科技发展有限公司 | 一种小核酸分子快递技术 |
| EP3038623A4 (en) | 2013-09-09 | 2017-04-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| KR20160070066A (ko) | 2013-09-09 | 2016-06-17 | 멜린타 테라퓨틱스, 인크. | 항균 화합물, 및 이의 제조 방법 및 이용 방법 |
| CA2979342A1 (en) | 2015-03-11 | 2016-09-15 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| AU2016341208A1 (en) * | 2015-10-20 | 2018-05-10 | Sorrento Therapeutics, Inc. | Intracellular delivery compounds |
| WO2017193016A1 (en) | 2016-05-06 | 2017-11-09 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| WO2018029517A1 (en) | 2016-08-08 | 2018-02-15 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
| US20190218255A1 (en) * | 2016-09-16 | 2019-07-18 | Olipass Corporation | Scn9a antisense oligonucleotides |
| KR102511482B1 (ko) * | 2016-10-11 | 2023-03-17 | 올리패스 주식회사 | 히프 1-알파 안티센스 올리고뉴클레오티드 |
| ES3038159T3 (en) | 2016-11-16 | 2025-10-09 | Academisch Ziekenhuis Leiden | Substances for targeting various selected organs or tissues |
| AU2017385962B2 (en) * | 2016-12-30 | 2021-09-02 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
| TWI769208B (zh) * | 2017-01-06 | 2022-07-01 | 韓商奧利通公司 | Ｓｎａｐ２５反義寡核苷酸 |
| SG11201905601VA (en) * | 2017-01-24 | 2019-08-27 | Olipass Corp | Scn9a antisense pain killer |
| KR20190011181A (ko) * | 2017-07-24 | 2019-02-01 | 올리패스 주식회사 | 티로시나아제 안티센스 올리고뉴클레오티드 |
| KR102236495B1 (ko) * | 2017-07-24 | 2021-04-06 | 올리패스 주식회사 | 티로시나아제 안티센스 올리고뉴클레오티드 |
| TWI832851B (zh) * | 2018-05-18 | 2024-02-21 | 韓商奧利通公司 | 基質金屬蛋白酶-1之反義寡核苷酸 |
| KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
| CN114502571B (zh) * | 2019-07-18 | 2024-09-13 | 奥利通公司 | 黑素亲和素反义寡核苷酸 |
| KR102934598B1 (ko) | 2020-06-05 | 2026-03-05 | 넥스올리고(주) | 신규한 몰포리노 올리고뉴클레오티드 유도체 |
| KR20240172540A (ko) * | 2023-06-01 | 2024-12-10 | 주식회사 기프티드엠에스 | 세포 투과가 가능한 펩타이드-핵산 올리고머를 유효성분으로 포함하는 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물 |
| KR102633299B1 (ko) | 2023-09-08 | 2024-02-02 | 국방과학연구소 | 세포 투과가 가능한 펩타이드 핵산 올리고머를 유효성분으로 포함하는 한탄바이러스 감염 질환 치료용 약학적 조성물 |
| WO2025219570A1 (en) | 2024-04-17 | 2025-10-23 | Johannes Kepler Universität Linz | Composition for inhibiting protein translocation and methods using the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| DK51092D0 (da) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US6133444A (en) | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
| US6617422B1 (en) | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
| DE10019136A1 (de) | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung |
| CN1814614A (zh) * | 2005-02-06 | 2006-08-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 核酸、肽核酸衍生物及它们的用途 |
| US7960360B2 (en) | 2006-11-13 | 2011-06-14 | Jennifer Rubin Grandis | Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents |
-
2009
- 2009-03-12 KR KR1020090021040A patent/KR20090098710A/ko not_active Withdrawn
- 2009-03-13 NZ NZ587448A patent/NZ587448A/en unknown
- 2009-03-13 RU RU2010135635/04A patent/RU2564032C2/ru active
- 2009-03-13 JP JP2010550603A patent/JP5620282B2/ja active Active
- 2009-03-13 AU AU2009224149A patent/AU2009224149B2/en active Active
- 2009-03-13 CA CA2715844A patent/CA2715844C/en active Active
- 2009-03-13 CN CN200980109059.1A patent/CN102015628B/zh active Active
- 2009-03-13 EP EP20090719041 patent/EP2268607B9/en active Active
- 2009-03-13 PT PT97190417T patent/PT2268607E/pt unknown
- 2009-03-13 DK DK09719041.7T patent/DK2268607T5/en active
- 2009-03-13 ES ES09719041.7T patent/ES2533769T3/es active Active
- 2009-03-13 MX MX2010009687A patent/MX2010009687A/es active IP Right Grant
- 2009-03-13 WO PCT/KR2009/001256 patent/WO2009113828A2/en not_active Ceased
- 2009-03-13 PL PL09719041T patent/PL2268607T3/pl unknown
- 2009-03-13 KR KR1020107018868A patent/KR101598423B1/ko active Active
- 2009-03-13 BR BRPI0906104A patent/BRPI0906104B8/pt active IP Right Grant
- 2009-03-13 US US12/922,322 patent/US8680253B2/en active Active
-
2010
- 2010-08-15 IL IL207617A patent/IL207617A/en active IP Right Grant
- 2010-08-20 ZA ZA2010/05960A patent/ZA201005960B/en unknown
-
2013
- 2013-12-17 US US14/109,327 patent/US8884008B2/en active Active
- 2013-12-18 US US14/133,045 patent/US8859766B2/en active Active
- 2013-12-19 US US14/134,279 patent/US8895734B2/en active Active
-
2014
- 2014-12-30 IL IL236515A patent/IL236515A0/en active IP Right Grant
- 2014-12-30 IL IL236513A patent/IL236513A0/en active IP Right Grant
- 2014-12-30 IL IL236514A patent/IL236514A0/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0906104A2 (pt) | "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto" | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| BRPI0810928A2 (pt) | "composição farmacêutica" | |
| BRPI0905680A2 (pt) | "composição farmacêutica de uma composição farmacêutica" | |
| BRPI0913379A2 (pt) | formulações farmacêuticas sólidas compreendendo bibw 2992 | |
| NO20090578A (no) | Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre | |
| ZA200809002B (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
| EP2037738A4 (en) | feeding method | |
| DK2303330T4 (da) | Farmaceutiske sammensætninger til behandling af parkinsons sygdom | |
| BRPI0809661A2 (pt) | Composição farmacêutica estabilizada contendo pregabalina | |
| EP2094118A4 (en) | IMPROVED PERACIC ACID COMPOSITION | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| AP2008004671A0 (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
| EP2205218A4 (en) | ESOMEPRAZOLE-CONTAINING PHARMACEUTICAL COMPOSITION | |
| BRPI0720234A2 (pt) | Composição farmacêutica | |
| BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
| BRPI0916069A2 (pt) | "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição" | |
| IL192415A0 (en) | Pharmaceutical composition for the treatment of nail diseases | |
| IL193372A0 (en) | Pharmaceutical composition comprising oseltamivir phosphate | |
| EP2006331A4 (en) | polylactic acid | |
| DK2271321T3 (da) | Farmaceutisk sammensætning 271 | |
| BRPI0810962A2 (pt) | Formulações de aminoácidos n-halogenados com compostos anti-inflamatórios | |
| BRPI0815531A2 (pt) | "compostos, composição farmacêutica, composição cosmética, uso cosmético de uma composição e uso de um composto" | |
| BRPI0814115A2 (pt) | Composição farmacêutica compreendendo composto de 11-deóxi-prostaglandina e método para estabilizar o composto | |
| EP2263671A4 (en) | AMID DERIVATIVE PHARMACEUTICAL COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |